Table 6.
Univariate and multivariate analyses for OS and DFS among patients with gastric cancer.
| Overall survival | Disease-free survival | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate | Multivariate | Univariate | Multivariate | |||||||||
| HR | 95% CI | P value | HR | 95% CI | P value | HR | 95% CI | P value | HR | 95% CI | P value | |
| CONUT (≥2 vs <2) | 2.185 | 1.674–2.853 | .000 | – | – | – | 1.756 | 1.280–2.408 | .000 | – | – | – |
| CEA (≥9.5 vs <9.5) | 1.819 | 1.273–2.599 | .001 | – | – | – | 1.681 | 1.105–2.557 | .015 | – | – | – |
| CONUT-CEA score-2 (1 vs 0) | 2.083 | 1.582–2.744 | .000 | 1.647 | 1.241–2.188 | .001 | 1.757 | 1.272–2.427 | .001 | 1.452 | 1.046–2.016 | .026 |
| CONUT-CEA score-2 (2 vs 0) | 3.339 | 2.028–5.499 | .000 | 2.358 | 1.412–3.940 | .001 | 2.475 | 1.352–4.531 | .003 | 1.980 | 1.072–3.656 | .029 |
| Age (≥75 vs <75) | 2.423 | 1.713–3.426 | .000 | 2.400 | 1.672–3.444 | .000 | 1.511 | 0.964–2.369 | .072 | – | – | – |
| Sex (female vs male) | 1.323 | 0.997–1.756 | .052 | – | – | – | 1.375 | 0.990–1.909 | .057 | – | – | – |
| Smoking | 0.783 | 0.566–1.083 | .139 | – | – | – | 0.727 | 0.491–1.075 | .110 | – | – | – |
| Alcohol | 0.964 | 0.602–1.542 | .878 | – | – | – | 0.888 | 0.504–1.566 | .683 | – | – | – |
| BMI (≥25 vs <25) | 0.730 | 0.485–1.098 | .131 | – | – | – | 0.811 | 0.508–1.295 | .381 | – | – | – |
| Tumor location (distal vs proximal) | 0.778 | 0.597–1.014 | .063 | – | – | – | 0.846 | 0.621–1.153 | .289 | – | – | – |
| T stage (T2 vs T1) | 2.450 | 1.18–5.086 | .016 | – | – | – | 2.132 | 0.898–5.060 | .086 | – | – | – |
| T stage (T3 vs T1) | 5.262 | 2.844–9.736 | .000 | – | – | – | 4.615 | 2.262–9.418 | .000 | – | – | – |
| T stage (T4 vs T1) | 6.660 | 3.682–12.045 | .000 | – | – | – | 5.926 | 2.990–11.747 | .000 | – | – | – |
| N stage (N1 vs N0) | 2.810 | 1.822–4.335 | .000 | – | – | – | 2.878 | 1.660–4.988 | .000 | – | – | – |
| N stage (N2 vs N0) | 4.028 | 2.646–6.133 | .000 | – | – | – | 5.724 | 3.465–9.457 | .000 | – | – | – |
| N stage (N3 vs N0) | 5.850 | 4.031–8.490 | .000 | – | – | – | 6.221 | 3.907–9.907 | .000 | – | – | – |
| TNM stage (II vs I) | 3.889 | 2.254–6.710 | .000 | 2.721 | 1.543–4.799 | .001 | 3.813 | 1.916–7.588 | .000 | 2.820 | 1.378–5.772 | .005 |
| TNM stage (III vs I) | 8.697 | 5.179–14.606 | .000 | 5.848 | 3.352–10.205 | .000 | 9.566 | 5.003–18.290 | .000 | 6.634 | 3.300–13.335 | .000 |
| Histological type (undifferentiated vs differentiated) | 1.523 | 1.145–2.026 | .004 | 1.104 | 0.813–1.498 | .526 | 1.637 | 1.164–2.304 | .005 | 1.063 | 0.742–1.524 | .737 |
| Complications (yes vs no) | 0.677 | 0.217–2.115 | .502 | – | – | – | 1.099 | 0.735–1.642 | .646 | – | – | – |
| Neurovascular invasion (yes vs no) | 2.619 | 1.988–3.451 | .000 | 1.563 | 1.158–2.110 | .004 | 2.735 | 1.969–3.799 | .000 | 1.475 | 1.033–2.104 | .032 |
| Adjuvant chemotherapy (present vs absent) | 1.279 | 0.974–1.680 | .076 | – | – | – | 1.118 | 0.816–1.532 | .487 | – | – | – |
ALB = albumin, BMI = body mass index, CEA = carcinoembryonic antigen, CONUT = controlling nutritional status, DFS = disease-free survival, OS = overall survival, TNM = Tumour-Node-Metastasis.